Table 1.
Phase 3 trials evaluating novel agent-based maintenance therapy after ASCT
→ indicates “followed by”; BORT, bortezomib; DEX, dexamethasone; EFS, event-free survival; IFNa, interferon-α; LEN, lenalidomide; PAM, pamidronate; PBO, placebo; PRED, prednisone; THAL, thalidomide; and TTP, time to progression.
* Significant OS advantage at 39 months disappeared with longer follow-up (7.5 years).20
† Meta-analysis reported in this review demonstrated that thalidomide maintenance was associated with a significant late OS benefit.16
